Posted by Michael Wonder on 13 Dec 2020
Though promising, gene therapies face durability and reimbursement headwinds
11 December 2020 - The promise of gene therapy is to cure diseases associated with faulty or missing genes. There’s enormous potential.
Just this month, at the annual American Society of Hematology meeting, it was shown that gene therapy stops bleeding in hemophilia.
Researchers reported that a single injection of a viral-mediated gene therapy vector decreases the bleeding rate among patients with Factor IX-related haemophilia B by 91% over a 6 month period.
